Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 815-820

  Powles, T ^a   Chowdhury, S ^b   Shamash, J ^a   Bazeos, A ^c   Gillessen, S ^a   Saunders, N ^a   Lim, L ^a   Sarwar, N ^a   Sadev, A ^a   Wilson, P ^a   Nathan, P ^d   Boleti, K ^e   Peters, J ^f   Agrawal, S ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

HPC; IGF 1; Renal cancer; Sunitinib

Indexed keywords

CD45 ANTIGEN; SOMATOMEDIN C; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CD34 SELECTION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY CANCER; LETHARGY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 79953319193     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq469     Document Type: Article

References (26)

1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
2. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111.
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
4. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
5. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
6. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): 5422-5428.
7. Sternberg C, Szczylik E, Lee PV et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009; 27: 15s (abstr 5021).
8. Khurdayan VK. Take-home message: are we "off target"? Drug News Perspect 2007; 20(5): 345-51.
9. Vroling L, van der Veldt AA, de Haas RR et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009; 12(1): 69-79.
10. Basu A, Hoerning A, Datta D et al. Cutting edge: vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol 2010; 184(2): 545-549.
11. Rasmuson T, Grankvist K, Jacobsen J et al. Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol 2004; 43(8): 744-748.
12. Montero AJ, Diaz-Montero CM, Millikan RE et al. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival. Ann Oncol 2009; 20(10): 1682-1687.
13. Hanley MB, Napolitano LA, McCune JM. Growth hormone-induced stimulation of multilineage human hematopoiesis. Stem Cells 2005; 23(8): 1170-1179.
14. Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer 2008; 6 (Suppl 1): S7-S13(Review).
15. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5(3): 213-226.
16. Gratama JW, Kraan J, Keeney M et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003; 5(1): 55-65.
17. Sutherland DR, Nayyar R, Acton E et al. Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers. Cytotherapy 2009; 11(5): 595-605.
18. Arslan O, Moog R. Mobilization of peripheral blood stem cells. Transfus Apher Sci 2007; 37(2): 179-185.
19. Powerski MJ, Henrich D, Sander A et al. CD133+CD34+ stem cells are mobilized after musculoskeletal surgery and target endothelium activated by surgical wound fluid. Langenbecks Arch Surg 2010 Mar 7. [Epub ahead of print].
20. Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70(3): 1063-1071.
21. Kontovinis LF, Papazisis KT, Touplikioti P et al. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009; 9: 82.
22. Ratajczak MZ, Kuczynski WI, Onodera K et al. A reappraisal of the role of insulinlike growth factor I in the regulation of human hematopoiesis. J Clin Invest 1994; 94(1): 320-327.
23. Desar IM, Mulder SF, Stillebroer AB et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 2009; 48(6): 927-931.
24. Wolter P, Beuselinck B, Pans S, Schöffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009; 48(4): 621-624.
25. Yakar S, Pennisi P, Wu Y et al. Clinical relevance of systemic and local IGF-I. Endocr Dev 2005; 9: 11-16 (Review).
26. Vroling L, Yuana Y, Schuurhuis GJ et al. VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. Thromb Haemost 2007; 98(2): 440-450.